Evidence map›Paper›PMID 39887627›Full record

ReviewJournal of cellular and molecular medicine2025

Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib.

Alessandro Broccoli, Marzia Del Re, Romano Danesi, Pier Luigi Zinzani

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alessandro BroccoliIRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.ORCID 0000-0001-5633-7313
Marzia Del ReDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Romano DanesiDepartment of Oncology and Hemato-Oncology, University of Milano, Milan, Italy.
Pier Luigi ZinzaniIRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bruton tyrosine kinase (BTK), the primary target of BTK inhibitors, is a key enzyme in the proliferation and survival pathway of neoplastic B-cells. BTK inhibitors are approved in many hematologic malignancies: chronic lymphocytic leukaemia, mantle cell lymphoma, marginal zone lymphoma, Waldenström macroglobulinaemia and follicular lymphoma. Second-generation BTK inhibitors display high target selectivity thus resulting in a reduction in off-target and off-tissue effects, better therapeutic index and improved tolerability. This paper summarizes the mechanisms of action of first and second generation BTK inhibitors and elucidates results in any disease setting, with a precise focus on zanubrutinib.

Indexed as

Agammaglobulinaemia Tyrosine KinaseHematologic NeoplasmsPiperidinesProtein Kinase InhibitorsPyrazolesPyrimidinesAnimalsAntineoplastic AgentsHumansTyrosine Kinase InhibitorsAgammaglobulinaemia Tyrosine KinaseAntineoplastic AgentsBTK protein, humanPiperidinesProtein Kinase InhibitorsPyrazolesPyrimidinesTyrosine Kinase InhibitorszanubrutinibBTK inhibitorschronic lymphocytic leukemiafollicular lymphomamantle cell lymphomamarginal zone lymphomaWaldenstrom macroglobulinemiazanubrutinib

Identifiers

PMID39887627
PMCPMC11783154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.